← back to search

Xue Geng

Beijing Institute of Technology · CN
Area of research
Oncology · Health, Toxicology and Mutagenesis
Research interest
Research interests include Cancer Immunotherapy and Biomarkers, Air Quality and Health Impacts, HER2/EGFR in Cancer Research, and Cancer Genomics and Diagnostics.
h-index
17
citations
1,049
works
114
NIH funding
primary concept
email

Recent publications

Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study
Nature Communications 2024cited by 24position: middledoi
Traditional Chinese medicine Jianpi therapy in exercise-induced fatigue
Medicine 2022cited by 1position: firstdoi
Predictive Value of QRS Fraction for Cardiovascular Death in Patients with Heart Failure: A Prospective Cohort Study in Acute Decompensated Heart Failure (Heb-ADHF)
Reviews in Cardiovascular Medicine 2022cited by 0position: middledoi
Long-term follow-up assessment of cardiac safety in SAFE-HEaRt, a clinical trial evaluating the use of HER2-targeted therapies in patients with breast cancer and compromised heart function
Breast Cancer Research and Treatment 2021cited by 31position: middledoi
Developmental Dysplasia of the Hip: An Examination of Care Practices of Pediatric Orthopaedic Surgeons in North America
Journal of Pediatric Orthopaedics 2020cited by 23position: middledoi
Prospective evaluation of the cardiac safety of HER2-targeted therapies in patients with HER2-positive breast cancer and compromised heart function: the SAFE-HEaRt study
Breast Cancer Research and Treatment 2019cited by 142position: middledoi
Progranulin protects against renal ischemia/reperfusion injury in mice
Kidney International 2015cited by 102position: middledoi
Critical role of histone demethylase RBP2 in human gastric cancer angiogenesis
Molecular Cancer 2014cited by 65position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Mark Hofmeyer · MedStar Washington Hospital Center2 papers (2019–2021)Raquel Nunes · Amgen (United States)2 papers (2019–2021)Ana Barac · Inova Fairfax Hospital2 papers (2019–2021)Ming Tan · University of Hong Kong2 papers (2019–2021)Pia Herbolsheimer · AstraZeneca (Netherlands)2 papers (2019–2021)Anthony F. Yu · Memorial Sloan Kettering Cancer Center2 papers (2019–2021)Federico M. Asch · MedStar Health2 papers (2019–2021)Sandra M. Swain · MedStar Health2 papers (2019–2021)Chau T. Dang · Artistic Realization Technologies2 papers (2019–2021)Claudine Isaacs · Georgetown University2 papers (2019–2021)Karen L. Smith · Massachusetts General Hospital2 papers (2019–2021)Monvadi B. Srichai · New York University2 papers (2019–2021)Christopher Gallagher · University of Kentucky2 papers (2019–2021)Filipa Lynce · Harvard University2 papers (2019–2021) · 1 papers (2020–2020)Fan Yi · Nanjing Tech University1 papers (2015–2015)Lupeng Li · Shandong University1 papers (2014–2014) · 1 papers (2014–2014)Paula R. Pohlmann · The University of Texas MD Anderson Cancer Center1 papers (2021–2021)Meng Zhou · Shandong University1 papers (2015–2015)